# news & insights ## Advancing the future of oncology through data, science, and discovery. Stay up to date on how Pathos AI is transforming oncology drug development — from major funding milestones and clinical advancements to industry collaborations that shape the future of biopharma. ## category: - [funding](https://www.pathos.com/news/funding#NewsFunding) - [leadership](https://www.pathos.com/news/leadership#NewsLeadership) - [collaboration](https://www.pathos.com/news/collaboration#NewsCollaboration) - [clinical updates](https://www.pathos.com/news#PressReleases) --- ### [Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor](https://www.pathos.com/pathos-ai-doses-first-patient-in-phase-1b-2a-clinical-trial-of-pocenbrodib-a-cbp-p300-inhibitor) March 20, 2025 CHICAGO, Mar. 20, 2025 (GLOBE NEWSWIRE) — Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced the first patient has been dosed in the Company’s Phase 1b/2a clinical trial evaluating pocenbrodib, a CBP/p300 inhibitor, alone and in combination with abiraterone acetate, olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC), (P300-02-001, NCT06785636). Pocenbrodib is Pathos’ first clinical-stage asset in its pipeline. “The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated biomarker strategy that identifies patients most likely to benefit,” said Dr. Jens Renstrup, Chief Medical Officer. “This study builds on the previously reported data from COURAGE study (NCT04575766) in metastatic castration-resistant prostate cancer and reinforces our confidence in pocenbrodib’s potential to improve outcomes for these patients.” ### About Pocenbrodib Pocenbrodib is an oral, small molecule inhibitor that has the potential to provide clinical benefit for patients with advanced prostate cancer, either alone or in combination with other treatments. Pocenbrodib works by inhibiting CREBBP/EP300 (also known as CBP/p300), which are proteins that activate genes that promote cancer cell growth and proliferation. ### About Pathos AI Pathos is a clinical-stage biotechnology company powered by advanced AI that is re-engineering drug development by optimizing patient selection strategies in phase 2 clinical trials. Pathos has raised over $100 million to expand its AI platform and bring targeted treatments to patients faster. --- ### [Pathos Expands Pipeline With Worldwide License of Phase 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor](https://www.pathos.com/pathos-expands-pipeline-with-worldwide-license-of-phase-2-ready-program-a-brain-penetrant-prmt5-inhibitor) August 15, 2024 Chicago – Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, announced today the world-wide license of PRT811, a potent, selective, and orally bioavailable brain penetrant SAM-competitive PRMT5 inhibitor from Prelude Therapeutics. ### About P-500 P-500 (previously PRT811) is a selective, brain-penetrant small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) that has the potential to provide clinical benefit for patients with advanced solid tumors, including high-grade glioma and uveal melanoma. ### About Pathos Pathos is a clinical-stage biotechnology company focused on re-engineering drug development, leveraging the power of AI technologies to bring precision medicines to market through partnership with biopharmaceutical companies. --- ### [Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor](https://www.pathos.com/pathos-launches-precision-oncology-pipeline-with-license-of-first-phase-i-program-a-cbp-p300-inhibitor) May 23, 2023 Pathos obtains worldwide rights from Novo Nordisk for the development of CBP/p300 inhibitor, FT-7051. ### About P-300 P-300 is an oral, small molecule inhibitor that has the potential to provide clinical benefit for patients with advanced prostate cancer, either alone or in combination with other treatments. P-300 works by inhibiting CREBBP/EP300 (also known as CBP/p300), impacting key cancer drivers. ### About Pathos Pathos is a biotechnology company focused on revolutionizing precision medicine in cancer by leveraging the power of machine learning.